PTCT Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

237.29M

+11.31%

-0.439

-48.37%

194.19M

-83.49%

-0.561

-105.59%

213.16M

+19.17%

-0.377

-54.56%

Estimates Revision

The market is revising Downward the revenue expectations for PTC Therapeutics, Inc. (PTCT) for FY2025, with the revenue forecasts being adjusted by -0.29% over the past three months. During the same period, the stock price has changed by 17.45%.

Revenue Estimates for FY2025

Revise Downward

-0.29%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-0.59%

In Past 3 Month

Stock Price

Go Up

+17.45%

In Past 3 Month

15 Analyst Rating

Wall Street analysts forecast PTCT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PTCT is 76.18 USD with a low forecast of 50.00 USD and a high forecast of 118.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

10 Buy

4 Hold

1 Sell

Moderate Buy

Current: 0.000

Low

50.00

Averages

76.18

High

118.00

Current: 0.000

Low

50.00

Averages

76.18

High

118.00

Morgan Stanley

Overweight

maintain

$78 -> $90

2026-01-08

New

Reason

Morgan Stanley

Price Target

$78 -> $90

2026-01-08

New

maintain

Overweight

Reason

Morgan Stanley raised the firm's price target on PTC Therapeutics to $90 from $78 and keeps an Overweight rating on the shares. The firm sees a continuation of U.S. small-to-mid cap biotech's outperformance in 2026 as commercial names transition from "capital consumers to producers" and Large Cap Biopharma faces a looming patent cliff, the analyst tells investors in an outlook note for the group.

Goldman Sachs

NULL -> Sell

downgrade

$44 -> $50

2025-11-06

Reason

Goldman Sachs

Price Target

$44 -> $50

2025-11-06

downgrade

NULL -> Sell

Reason

Goldman Sachs raised the firm's price target on PTC Therapeutics to $50 from $44 and keeps a Sell rating on the shares.

Goldman Sachs

Sell

maintain

$44 -> $50

2025-11-05

Reason

Goldman Sachs

Price Target

$44 -> $50

2025-11-05

maintain

Sell

Reason

Goldman Sachs raised the firm's price target on PTC Therapeutics to $50 from $44 and keeps a Sell rating on the shares. PTC Therapeutics reported stronger-than-expected Q3 results driven by robust early Sephience sales and solid performance from the legacy Duchenne muscular dystrophy franchise, the analyst tells investors in a research note. Sephience's launch showed encouraging momentum with broad COE engagement and favorable early payer dynamics, though DMD revenue continued to decline sequentially. While early uptake supports confidence in Sephience's trajectory, U.S. sales targets above $1B appear ambitious, and attention now turns to ongoing launch progress, the upcoming votoplam FDA update, and pipeline developments at December's R&D day, Goldman says.

TD Cowen

Joseph Thome

Hold

maintain

$50 -> $63

2025-11-05

Reason

TD Cowen

Joseph Thome

Price Target

$50 -> $63

2025-11-05

maintain

Hold

Reason

TD Cowen analyst Joseph Thome raised the firm's price target on PTC Therapeutics to $63 from $50 and keeps a Hold rating on the shares. The firm said they posted a solid topline beat where nitial Sephience sales of $19.2MM beat the $4MM consensus, and surpassed the higher end of investor expectations.

RBC Capital

Outperform

maintain

$70 -> $82

2025-11-05

Reason

RBC Capital

Price Target

$70 -> $82

2025-11-05

maintain

Outperform

Reason

RBC Capital raised the firm's price target on PTC Therapeutics to $82 from $70 and keeps an Outperform rating on the shares after its Q3 earnings beat. The company's Sephience launch appears to be off to an excellent start, likely surpassing the growing expectations into the quarter, and with signals supporting good near/medium-term durability, the analyst tells investors in a research note.

Citi

Neutral

maintain

$50 -> $75

2025-11-05

Reason

Citi

Price Target

$50 -> $75

2025-11-05

maintain

Neutral

Reason

Citi raised the firm's price target on PTC Therapeutics to $75 from $50 and keeps a Neutral rating on the shares following the Q3 report. The firm says PTC reported a strong first quarter of Sephience sales.

Valuation Metrics

The current forward P/E ratio for PTC Therapeutics Inc (PTCT.O) is -50.06, compared to its 5-year average forward P/E of -12.43. For a more detailed relative valuation and DCF analysis to assess PTC Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-12.43

Current PE

-50.06

Overvalued PE

-0.42

Undervalued PE

-24.44

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

22.64

Current EV/EBITDA

147.89

Overvalued EV/EBITDA

217.80

Undervalued EV/EBITDA

-172.52

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

4.30

Current PS

7.00

Overvalued PS

5.63

Undervalued PS

2.98

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 3181.08% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

PTCT News & Events

Events Timeline

No data

News

5.0

01-08Newsfilter

PTC Therapeutics Grants 300 RSUs to Attract New Employee

5.0

01-08PRnewswire

PTC Therapeutics Grants 300 RSUs to Attract New Employee

8.5

2025-12-31Benzinga

Royalty Pharma Acquires Evrysdi Royalty for $240 Million Upfront

People Also Watch

Frequently Asked Questions

What is PTC Therapeutics Inc (PTCT) stock price today?

The current price of PTCT is 77.53 USD — it has increased 0.88 % in the last trading day.

What is PTC Therapeutics Inc (PTCT)'s business?

PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).

What is the price predicton of PTCT Stock?

What is PTC Therapeutics Inc (PTCT)'s revenue for the last quarter?

PTC Therapeutics Inc revenue for the last quarter amounts to 211.01M USD, increased 7.23 % YoY.

What is PTC Therapeutics Inc (PTCT)'s earnings per share (EPS) for the last quarter?

PTC Therapeutics Inc. EPS for the last quarter amounts to 0.18 USD, decreased -112.95 % YoY.

What changes have occurred in the market's expectations for PTC Therapeutics Inc (PTCT)'s fundamentals?

How many employees does PTC Therapeutics Inc (PTCT). have?

PTC Therapeutics Inc (PTCT) has 939 emplpoyees as of January 10 2026.

What is PTC Therapeutics Inc (PTCT) market cap?

Today PTCT has the market capitalization of 6.22B USD.